Edesa Biotech Q3 net loss $5.79M ($0.37/sh); Phase 3 ARDS study expanded; Phase 2b on track

Edesa Biotech, Inc.

Net loss for Q3 fiscal 2022: $5.79M ($0.37/sh) vs $4.76M ($0.36/sh) in prior year; nine-month loss $14.74M ($1.04/sh).
Phase 3 ARDS study for Covid-19 expanded to second cohort; parallel recruitment underway.
Phase 2b ACD study expects to randomize all 210 subjects by Q4 2022 with topline data in early 2023.
Cash and equivalents $12.81M; working capital $9.52M at June 30, 2022.
Operating expenses for Q3 were $5.80M, down from $6.07M YoY, driven by lower G&A and share-based compensation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.